Veda Vyas, MD
Child & Adolescent Psychiatry · Winter Park, FLNPI 1417052309
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Neurocrine Biosciences, Inc. at 32.2% of the total. 2025 is the largest year on record at $1,308, 5.0 times the $262 reported in 2019.
Across 151 payments — averaging $24.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neurocrine Biosciences, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$793
- Otsuka America Pharmaceutical, Inc.$404
- Supernus Pharmaceuticals, Inc.$280
- Ironshore Pharmaceuticals Inc.$241
- Lundbeck LLC$129
- plus $634 from 9 others
What the payments were for
- Food & beverage$3,54797%
- Education$1113%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neurocrine Biosciences, Inc. | 50 | $1,177 |
| Teva Pharmaceuticals USA, Inc. | 24 | $793 |
| Otsuka America Pharmaceutical, Inc. | 14 | $404 |
| Supernus Pharmaceuticals, Inc. | 20 | $280 |
| Ironshore Pharmaceuticals Inc. | 11 | $241 |
| Lundbeck LLC | 6 | $129 |
| Axsome Therapeutics, Inc. | 4 | $122 |
| Insulet Corporation | 1 | $119 |
| AbbVie | 6 | $112 |
| Tris Pharma Inc | 6 | $105 |
| Johnson & Johnson | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
| Corium, LLC | 1 | $23 |
| E.r. Squibb & Sons, L.L.C. | 1 | $18 |
| Indivior Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Austedo XR$233
- INGREZZA$122
- Omnipod$119
- ABILIFY MAINTENA$111
- ABILIFY ASIMTUFII$111
How this compares
$3,658 in reported general payments places this provider in the 80th percentile of 206 child & adolescent psychiatry providers in Florida.
See all child & adolescent psychiatry providers in Florida →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 11 | $81,552 |
| Invega SustennaPaliperidone Palmitate | 15 | $46,033 |
| VraylarCariprazine Hcl | 29 | $40,471 |
| PerserisRisperidone | 15 | $38,456 |
| RexultiBrexpiprazole | 12 | $16,908 |
| Lurasidone Hcl | 89 | $15,812 |
| Risperdal ConstaRisperidone Microspheres | 14 | $15,218 |
| Ziprasidone Hcl | 292 | $12,147 |
| Chlorpromazine Hcl | 41 | $6,475 |
| Divalproex Sodium | 146 | $4,911 |
| Naltrexone Hcl | 105 | $4,673 |
| Quetiapine Fumarate | 404 | $4,482 |
| Divalproex Sodium ErDivalproex Sodium | 130 | $4,083 |
| Olanzapine | 188 | $3,800 |
| Oxcarbazepine | 49 | $2,732 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $1,177 | $81,55211 claims |
| Johnson & JohnsonInvega Sustenna, Risperdal Consta | $62 | $61,25129 claims |
| AbbVieVraylar | $112 | $40,47129 claims |
| Indivior Inc.Perseris | $13 | $38,45615 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $404 | $16,90812 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 206 child & adolescent psychiatry providers in Florida.
Other child & adolescent psychiatry in Winter Park
- Craig KuninsGulfport$265K
- Elias SarkisGainesville$169K
- Jeffrey AlvaroSt Petersburg$87K
- Rosa Negron MunozLakeland$39K
- Sean HoranMiami$17K
- Rachel AgustinesLargo$16K
- Carlos BorgeSarasota$15K
- Justin SpoonerPonte Vedra Beach$12K
- Bhaskar RajuOrlando$11K
- Americo PadillaMiami$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.